Literature DB >> 17935134

Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line.

Massimiliano Cariati1, Ali Naderi, John P Brown, Matthew J Smalley, Sarah E Pinder, Carlos Caldas, Anand D Purushotham.   

Abstract

The identification of mammary epithelial stem cells raises the hypothesis that these cells may be crucial in the pathogenesis of breast cancer. To further support this, a highly tumourigenic sub-population of cancer cells has recently been identified in primary and metastatic breast cancer samples. In this study, a sub-population of cells displaying features normally attributed to stem cells was identified within the breast cancer cell line MCF-7. This sub-population is capable of growth in anchorage-independent conditions as spherical organoids, displays resistance to proapoptotic agents and significantly greater tumourigenicity than its parental line, with as few as 1,000 cells able to form tumours in immunodeficient mice. Cells within this sub-population can be enriched by serial passages in anchorage-independence, and are characterized by over-expression of the adhesion molecule alpha6-integrin. Alpha-6 integrin proves to be required for the growth and survival of these cells, as the knockdown of ITGA6 causes mammosphere-derived cells to lose their ability to grow as mammospheres and abrogates their tumourigenicity in mice. These findings support the existence of a highly tumourigenic sub-population in breast cancer cells. Furthermore, it shows alpha6-integrin as a potential therapeutic target aimed at tumour-generating subsets of breast cancer cells. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17935134     DOI: 10.1002/ijc.23103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  100 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

2.  3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells.

Authors:  E Buommino; V Tirino; A De Filippis; F Silvestri; R Nicoletti; M L Ciavatta; G Pirozzi; M A Tufano
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

3.  TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.

Authors:  Gianluca Storci; Pasquale Sansone; Sara Mari; Gabriele D'Uva; Simona Tavolari; Tiziana Guarnieri; Mario Taffurelli; Claudio Ceccarelli; Donatella Santini; Pasquale Chieco; Kenneth B Marcu; Massimiliano Bonafè
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

4.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

5.  α6-Integrin is required for the adhesion and vasculogenic potential of hemangioma stem cells.

Authors:  David M Smadja; Coralie L Guerin; Elisa Boscolo; Ivan Bieche; John B Mulliken; Joyce Bischoff
Journal:  Stem Cells       Date:  2014-03       Impact factor: 6.277

Review 6.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

7.  Biophysical Regulation of Cancer Stem/Initiating Cells: Implications for Disease Mechanisms and Translation.

Authors:  Joseph Chen; Sanjay Kumar
Journal:  Curr Opin Biomed Eng       Date:  2017-05-19

8.  Regulated splicing of the α6 integrin cytoplasmic domain determines the fate of breast cancer stem cells.

Authors:  Hira Lal Goel; Tatiana Gritsko; Bryan Pursell; Cheng Chang; Leonard D Shultz; Dale L Greiner; Jens Henrik Norum; Rune Toftgard; Leslie M Shaw; Arthur M Mercurio
Journal:  Cell Rep       Date:  2014-04-24       Impact factor: 9.423

9.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

10.  Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.

Authors:  Ines Macias-Perez; Corina Borza; Xiwu Chen; Xuexian Yan; Raquel Ibanez; Glenda Mernaugh; Lynn M Matrisian; Roy Zent; Ambra Pozzi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.